Key Documents

View All Documentation

P0080

Pranlukast hemihydrate

Name: Pranlukast hemihydrate
Brand: SIGMA

≥98% (HPLC), CysLT1 receptor antagonist, solid

Synonym(s):

8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₇H₂₃N₅O₄· 0.5 H₂O

CAS Number:

150821-03-7

Molecular Weight:

490.51

UNSPSC Code:

51111800

PubChem Substance ID:

329820009

NACRES:

NA.77

MDL number:

MFCD24539454

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Pranlukast hemihydrate, ≥98% (HPLC), white, solid

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: ≥10 mg/mL, H₂O: insoluble

storage temp.

−20°C

SMILES string

O.O=C(Nc1cccc2C(=O)C=C(Oc12)c3nnn[nH]3)c4ccc(OCCCCc5ccccc5)cc4.O=C(Nc6cccc7C(=O)C=C(Oc67)c8nnn[nH]8)c9ccc(OCCCCc%10ccccc%10)cc9

InChI

1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2

InChI key

MSXTUBJFNBZPGC-UHFFFAOYSA-N

Related Categories

Bioactive Small Molecules

Biochem/physiol Actions

Pranlukast is a subtype specific CysLT1 receptor antagonist.

Pranlukast is a subtype specific CysLT1 receptor antagonist. Leukotrienes are involved in the inflammation response and are divided into two main classes; leukotriene B4 and cysteinyl-substituted leukotrienes.

Features and Benefits

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

GHS07

signalword

Warning

hcodes

H302,H315,H319,H335,H413

pcodes

P273 - P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells.

Inés Velázquez-Quesada et al.

Drug design, development and therapy, 14, 1799-1811 (2020-06-05)

Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs.

Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization.

Eun-Sol Ha et al.

Drug design, development and therapy, 9, 3257-3266 (2015-07-08)

The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral bioavailability using a surface-modified microparticle. Based on solubility measurements, surface-modified pranlukast hemihydrate microparticles were manufactured using the spray-drying method with hydroxypropylmethyl

Global Trade Item Number

SKU	GTIN
P0080-5MG	04061832785806
P0080-25MG	04061832785790

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service